Discussion on the Technical Development of Pediatric Pharmacovigilance

Abstract

Abstract: This article is based on the theory and the practice of pharmacovigilance(PV), and combined with the essential character of pediatric medication. The writer discusses on the special characteristics of pediatric PV, the role and responsibilities of different stakeholders, PV before authorization of a pediatric indication and PV for products on the market. We try to establish the frame of pediatric PV, and hope this pilot helpful for the practice of PV on special population like children.

Key words: medicines used by the pediatric population, pharmacovigilance, development

CLC Number:

R954

SHEN Lu, DU Xiao-xi. Discussion on the Technical Development of Pediatric Pharmacovigilance[J]. Chinese Journal of Pharmacovigilance, 2011, 8(4): 220-224.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2011/V8/I4/220

References

[1] ICH.ICH E11 Note for Guidance on the Clinical Investigation of Medicinal Products in the Paediatric Population(CPMP/ICH/2711/99)[EB/OL].2000-01[2010-12-25].http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002926.pdf.
[2] EMEA CHMP Guideline on Risk Assessment of Medicinal Products on Human Reproduction andLactation: from Data to Labelling(EMEA/CHMP/203927/2005)[EB/OL].2006-03[2010-12-25].http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_gui-deline/2009/09/WC500002926.pdf.
[3] EMEA. CHMP guideline on conduct of pharmacovigilance for medicines used by the pediatric population （EMEA/CHMP/PhVWP/235910/2005- rev.1[EB/OL].2006-03[2011-01-01].http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003764.pdf.
[4] ICH. ICH S5(R2) Note for Guidance on the Detection of Toxicity to Reproduction for Medicinal Products&Toxicity to Male Fertility(CPMP/ICH/386/95)[EB/OL]. 2008-02[2011-01-01].http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003103.pdf.
[5] EMEA CHMP Guideline on the need for Non-Clinical Testing in Juvenile Animals on Human Pharmaceuticals for Paediatric Indicat-ions(EMEA/CHMP/SWP/169215/2005)[EB/OL]. 2008-01[2011-01-01].http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003305.pdf.
[6] Evans W E,Hom Y Y,Bomgaars L,et al. Preponderance of thiopurine-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathiopurine[J].J clinoncol.2001,19(8):2293-2301.
[7] EMEA CHMP Guideline on Risk Management System for Medicinal Products for Human Use(EMEA/CHMP/96268/2005) [EB/OL]. 2005 -11-14[2011-01-01].http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004888.pdf.
[8] ICH. ICH E2C(R1) Note for Guidance on Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs (CPMP/ICH/288/95) and Addendum [EB/OL]. 1995-12[2011-01-01].http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/12/WC500017234.pdf.
[9] EMEA EWP Guideline on Clinical Trials in Small Populations (CHMP/EWP/83561/2005)[EB/OL].2005-01-27[2011-01-01].http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003766.pdf.
[10] Evans S J, Waller P C, Davis S. Pharmacoepidemiol[J].Drug Saf, 2001,10(6):483-486.

[1]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[2]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[3]	LEI Jianlin, WANG Na, WANG Wenzheng, WANG Yan. One Case of Phenytoin Intoxication Caused by Compound Phenytoin Sodium Ephedrine Hydrochloride and Theophylline Tablets [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 819-822.
[4]	SHEN Lu, LIU Cuili, WANG Yi, HAO Mingqiang, WANG Yali, ZHU Huijuan, WU Chen, YANG Yang. Precision Pharmacovigilance for Cell and Gene Therapy Products [J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 633-639.
[5]	MEI Haonan, ZHANG Ziyi, WANG Yuxi, WANG Hui, GUO Yu. Developmental Toxicity and Mechanisms of Acetaminophen Exposure during Pregnancy [J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 702-707.
[6]	MENG Xianghui, SUN Jiabei, Li Wenlong, JIA Juanjuan, CHENG Ming, HUANG Haiwei, SHI Yaqin. Zebrafish Toxicity of Trimethylsilanol: an Introduced Impurity in Fludeoxyglucose [¹⁸F] Injection [J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 397-402.
[7]	YANG Jingqi, XU Baohai, ZHANG Jing, JIANG Yang, SHI Fang. Pharmacovigilance for Traditional Chinese Patent Medicines for Orthopedics [J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 436-441.
[8]	YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao. A National Pharmacovigilance Management System in a New Era [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281.
[9]	LIU Ying, XIONG Shunyu, XIONG Huiyu, CAI Fei, XU Mengdan, WANG Qing, REN Wei, XU Yan. Methods for Assessment of MAH Compliance with GVP [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 282-285.
[10]	JIA Zhichao, HU Siyuan, LI Ruiben, XU Yaqian. Safety of Children’s Traditional Chinese Medicine Decoction Pieces in Clinical Application and Children’s Drug Development [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 324-328.
[11]	SUN Ximu, ZHOU Han, LI Yanming, GUO Peng, NIE Xiaolu. Signal Mining and Analysis of ICIs-Associated Thrombocytopenia Adverse Events Based on FAERS Database [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 23-28.
[12]	LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui. Developments and Prospects of Radiopharmaceuticals in China [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42.
[13]	JIANG Haiyan, ZHOU Tianyu, FAN Xiaoyu, LI Wanfang, BAO Jie, JIN Hongtao. Challenges to the current development of fixed-dose antitumor drug combinations [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 961-966.
[14]	GUO Shushu, JIANG Haiyan, FAN Xiaoyu, LI Wanfang, BAO Jie, MA Enlong, JIN Hongtao. Rationality of compound drug components against hypertension [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 973-977.
[15]	SUN Siman, JIANG Haiyan, FAN Xiaoyu, LI Wanfang, BAO Jie, WANG Chuan, JIN Hongtao. Research progress in anti-AIDS compound preparations [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 978-984.